CA2995970A1 - Electronic cigarette mixing agent composition systems - Google Patents
Electronic cigarette mixing agent composition systems Download PDFInfo
- Publication number
- CA2995970A1 CA2995970A1 CA2995970A CA2995970A CA2995970A1 CA 2995970 A1 CA2995970 A1 CA 2995970A1 CA 2995970 A CA2995970 A CA 2995970A CA 2995970 A CA2995970 A CA 2995970A CA 2995970 A1 CA2995970 A1 CA 2995970A1
- Authority
- CA
- Canada
- Prior art keywords
- cannabinoid
- distillate
- terpene
- propenediol
- electronic cigarette
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/007—Pulmonary tract; Aromatherapy
-
- A—HUMAN NECESSITIES
- A24—TOBACCO; CIGARS; CIGARETTES; SIMULATED SMOKING DEVICES; SMOKERS' REQUISITES
- A24B—MANUFACTURE OR PREPARATION OF TOBACCO FOR SMOKING OR CHEWING; TOBACCO; SNUFF
- A24B15/00—Chemical features or treatment of tobacco; Tobacco substitutes, e.g. in liquid form
- A24B15/10—Chemical features of tobacco products or tobacco substitutes
- A24B15/16—Chemical features of tobacco products or tobacco substitutes of tobacco substitutes
- A24B15/167—Chemical features of tobacco products or tobacco substitutes of tobacco substitutes in liquid or vaporisable form, e.g. liquid compositions for electronic cigarettes
-
- A—HUMAN NECESSITIES
- A24—TOBACCO; CIGARS; CIGARETTES; SIMULATED SMOKING DEVICES; SMOKERS' REQUISITES
- A24F—SMOKERS' REQUISITES; MATCH BOXES; SIMULATED SMOKING DEVICES
- A24F47/00—Smokers' requisites not otherwise provided for
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
- A61K31/05—Phenols
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pulmonology (AREA)
- Engineering & Computer Science (AREA)
- Alternative & Traditional Medicine (AREA)
- Biotechnology (AREA)
- Botany (AREA)
- Medical Informatics (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Pyrane Compounds (AREA)
Abstract
A vaporizable composition and method for forming the vaporizing article comprises collecting a cannabinoid distillate from a plant product, introducing a quantity of 1,3 propenediol to the cannabinoid distillate and homogenizing the cannabinoid distillate and the propenediol.
Description
ELECTRONIC CIGARETTE MIXING AGENT COMPOSITION SYSTEMS
BACKGROUND OF THE INVENTION
1. Field of Invention The present invention relates generally to the field of electronic cigarettes and more specifically to a cannabinoid-based liquid composition.
BACKGROUND OF THE INVENTION
1. Field of Invention The present invention relates generally to the field of electronic cigarettes and more specifically to a cannabinoid-based liquid composition.
2. Description of Related Art The electronic cigarette market is expanding greatly, because it allows the consumer smoker to preserve the ritual associated with the use of the cigarette without suffering the negative effects of the harmful substances that it contains.
The electronic cigarette or e-cigarette works with electricity without combustion.
It produces a mist of fine particles, commonly referred to as vapor or artificial smoke, which visually resembles the smoke produced by the combustion of tobacco. Oftentimes, the vapor is flavored (tobacco, mint, fruit, chocolate aroma, etc.) and it may or may not contain nicotine. In correctly manufactured and used e-cigarettes, the aerosol contains, according to available data, many fewer substances that are detrimental to health than the smoke of tobacco; in particular it does not contain solid particles, tar, other carcinogenic substances, or carbon monoxide (CO).
Cannabis has long been considered to have medicinal properties. Many states, such as Colorado, Washington, Oregon, California, Alaska, Maine, Hawaii, Nevada, Vermont, Montana, Rhode Island, New Mexico, Michigan, and New Jersey, allow the use of medicinal cannabis by persons with debilitating medical conditions, as certified by physicians.
Many vapors and other formulas which are presently being used comprise polyethylene glycol or propylene glycol which are mixing agents for cannabis oils and have known negative side effects (such as skin irritation and carcinogens known to cause cancer). A suitable solution is desired.
Various attempts have been made to solve problems found in electronic cigarettes art. Among these are found in: U.S. Patent and Publication Nos.
2016/0262443 to Piccirilli; 2016/0120225 to Mishra; and 9,339,062 to Hon. This prior art is representative of electronic cigarettes and related flavorants.
None of the above inventions and patents, taken either singly or in combination, is seen to describe the invention as claimed. Thus, a need exists for a reliable cannabis based liquid composition that mitigates harmful side effects, and to avoid the above-mentioned problems.
SUMMARY OF THE INVENTION
According to a first embodiment of the present invention there is disclosed a method for forming a vaporizing article comprising collecting a cannabinoid distillate from a plant product, introducing a quantity of 1,3 propenediol to the cannabinoid distillate and homogenizing the cannabinoid distillate and the propenediol.
The cannabinoid may be selected from the group consisting of delta-9-tetrahydrocannabinol (THC) and Cannabidiol (CBD). The cannabinoid may have a purity of at least 99%. The cannabinoid may comprise between 0 and 99 percent by volume of the vaporizing article.
The method may further comprise introducing at least one terpene to the cannabinoid distillate and propenediol. The terpene may be collected from a distillation process utilized to collect the cannabinoid distillate. The at least one terpene may comprise between 0 and 50 percent by volume of the vaporizing article. The method may further comprise introducing a quantity of an emulsifying agent to the vaporizing article before homogenizing.
According to a further embodiment of the present invention there is disclosed a vaporizable composition comprising cannabinoid and 1,3 propenediol. The cannabinoid may be selected from the group consisting of delta-9-
The electronic cigarette or e-cigarette works with electricity without combustion.
It produces a mist of fine particles, commonly referred to as vapor or artificial smoke, which visually resembles the smoke produced by the combustion of tobacco. Oftentimes, the vapor is flavored (tobacco, mint, fruit, chocolate aroma, etc.) and it may or may not contain nicotine. In correctly manufactured and used e-cigarettes, the aerosol contains, according to available data, many fewer substances that are detrimental to health than the smoke of tobacco; in particular it does not contain solid particles, tar, other carcinogenic substances, or carbon monoxide (CO).
Cannabis has long been considered to have medicinal properties. Many states, such as Colorado, Washington, Oregon, California, Alaska, Maine, Hawaii, Nevada, Vermont, Montana, Rhode Island, New Mexico, Michigan, and New Jersey, allow the use of medicinal cannabis by persons with debilitating medical conditions, as certified by physicians.
Many vapors and other formulas which are presently being used comprise polyethylene glycol or propylene glycol which are mixing agents for cannabis oils and have known negative side effects (such as skin irritation and carcinogens known to cause cancer). A suitable solution is desired.
Various attempts have been made to solve problems found in electronic cigarettes art. Among these are found in: U.S. Patent and Publication Nos.
2016/0262443 to Piccirilli; 2016/0120225 to Mishra; and 9,339,062 to Hon. This prior art is representative of electronic cigarettes and related flavorants.
None of the above inventions and patents, taken either singly or in combination, is seen to describe the invention as claimed. Thus, a need exists for a reliable cannabis based liquid composition that mitigates harmful side effects, and to avoid the above-mentioned problems.
SUMMARY OF THE INVENTION
According to a first embodiment of the present invention there is disclosed a method for forming a vaporizing article comprising collecting a cannabinoid distillate from a plant product, introducing a quantity of 1,3 propenediol to the cannabinoid distillate and homogenizing the cannabinoid distillate and the propenediol.
The cannabinoid may be selected from the group consisting of delta-9-tetrahydrocannabinol (THC) and Cannabidiol (CBD). The cannabinoid may have a purity of at least 99%. The cannabinoid may comprise between 0 and 99 percent by volume of the vaporizing article.
The method may further comprise introducing at least one terpene to the cannabinoid distillate and propenediol. The terpene may be collected from a distillation process utilized to collect the cannabinoid distillate. The at least one terpene may comprise between 0 and 50 percent by volume of the vaporizing article. The method may further comprise introducing a quantity of an emulsifying agent to the vaporizing article before homogenizing.
According to a further embodiment of the present invention there is disclosed a vaporizable composition comprising cannabinoid and 1,3 propenediol. The cannabinoid may be selected from the group consisting of delta-9-
-3-tetrahydrocannabinol (THC) and Cannabidiol (CBD). The cannabinoid may comprise between 0 and 99 percent by volume of the vaporizing article.
The vaporizable composition may further comprise a quantity of at least one terpene. The terpene may be collected from a distillation process utilized to collect the cannabinoid distillate. The at least one terpene may comprise between 0 and 50 percent by volume of the vaporizing article. The vaporizable composition may further comprise a quantity of an emulsifying agent.
Other aspects and features of the present invention will become apparent to those ordinarily skilled in the art upon review of the following description of specific embodiments of the invention in conjunction with the accompanying figures.
BRIEF DESCRIPTION OF THE DRAWINGS
In drawings which illustrate embodiments of the invention wherein similar characters of reference denote corresponding parts in each view, Figure 1 is a flow chart depicting a method of preparing a cannabinoid-based liquid composition according to a first embodiment of the present invention.
DETAILED DESCRIPTION
The present invention is directed to a cannabinoid based liquid composition.
In one embodiment of the present disclosure, electronic cigarette mixing agent composition systems may comprise a vaporizable cannabinoid liquid formulation for refillable cartridges or disposable electronic cigarettes or for using directly on atomizers or other controlled temperature vaporizers including cartomizers or wick systems that is safer, bio based, and more effective than currently used products.
Referring to Figure 1, a method of preparing a cannabinoid-based liquid composition according to a first embodiment of the present invention is illustrated generally at 10. The method begins by inputting cannabinoid containing material in step 20 for extraction. It will be appreciated that the
The vaporizable composition may further comprise a quantity of at least one terpene. The terpene may be collected from a distillation process utilized to collect the cannabinoid distillate. The at least one terpene may comprise between 0 and 50 percent by volume of the vaporizing article. The vaporizable composition may further comprise a quantity of an emulsifying agent.
Other aspects and features of the present invention will become apparent to those ordinarily skilled in the art upon review of the following description of specific embodiments of the invention in conjunction with the accompanying figures.
BRIEF DESCRIPTION OF THE DRAWINGS
In drawings which illustrate embodiments of the invention wherein similar characters of reference denote corresponding parts in each view, Figure 1 is a flow chart depicting a method of preparing a cannabinoid-based liquid composition according to a first embodiment of the present invention.
DETAILED DESCRIPTION
The present invention is directed to a cannabinoid based liquid composition.
In one embodiment of the present disclosure, electronic cigarette mixing agent composition systems may comprise a vaporizable cannabinoid liquid formulation for refillable cartridges or disposable electronic cigarettes or for using directly on atomizers or other controlled temperature vaporizers including cartomizers or wick systems that is safer, bio based, and more effective than currently used products.
Referring to Figure 1, a method of preparing a cannabinoid-based liquid composition according to a first embodiment of the present invention is illustrated generally at 10. The method begins by inputting cannabinoid containing material in step 20 for extraction. It will be appreciated that the
-4-cannabinoid containing may be selected to be cannabis, although other materials containing cannabinoids including other plants and synthetic sources may be utilized as well. In step 22, an extraction process is performed on the cannabinoid containing material, resulting in a cannabinoid essential oil being extracted therefrom. Several extraction methods may be useful in step 22, as will be set out further below. The resulting essential oil is then distilled in step 24 by heating the oil to a high temperature under a reduced pressure created by a vacuum pump to produce a distillate, as will be further set out below. In step 26, the distillate is collected by condensing the vapors produced in step on a cooled surface.
The cannabinoid containing material, in particular cannabis plants include a variety of hydrocarbon terpenes which vaporize at about the same temperature as THC. A select variety of terpenes may be isolated and stored according to known methods wherein at least one of the terpenes are added back into the distillate in step 28 with a mixing agent added in step 30. The mixing agent may be such as, by way of non-limiting example, 1,3-Propandiol, as will be further set out below. The dilution ratio using the mixing agent varies based on the desired potency of the final liquid to be vaporized. The product is homogenized in step 32 using such as, by way of non-limiting example, a mechanical homogenizer, as is commonly known, to produce the final product in step 34.
Optionally, the cannabinoid composition may include an emulsifying agent, such as, by way of non-limiting example, propylene glycol ester (PEG) or aloe vera. Although the present method is described as being utilized with a cannabinoid extract, it will be appreciated that any form of purified cannabinoids may be utilized, such as, by way of non-limiting example, solid cannabinoid products, such as shatter and isolates, wax, butter, live resins and oils.
The electronic cigarette mixing agent composition system may be used to create cannabinoid compositions in high, medium, and low potency dilution ratios as illustrated in Table 1 below. Furthermore, one ore more of the cannabinoid oil, or terpenes may be included in the composition at up to a quantity of 50% by volume.
The cannabinoid containing material, in particular cannabis plants include a variety of hydrocarbon terpenes which vaporize at about the same temperature as THC. A select variety of terpenes may be isolated and stored according to known methods wherein at least one of the terpenes are added back into the distillate in step 28 with a mixing agent added in step 30. The mixing agent may be such as, by way of non-limiting example, 1,3-Propandiol, as will be further set out below. The dilution ratio using the mixing agent varies based on the desired potency of the final liquid to be vaporized. The product is homogenized in step 32 using such as, by way of non-limiting example, a mechanical homogenizer, as is commonly known, to produce the final product in step 34.
Optionally, the cannabinoid composition may include an emulsifying agent, such as, by way of non-limiting example, propylene glycol ester (PEG) or aloe vera. Although the present method is described as being utilized with a cannabinoid extract, it will be appreciated that any form of purified cannabinoids may be utilized, such as, by way of non-limiting example, solid cannabinoid products, such as shatter and isolates, wax, butter, live resins and oils.
The electronic cigarette mixing agent composition system may be used to create cannabinoid compositions in high, medium, and low potency dilution ratios as illustrated in Table 1 below. Furthermore, one ore more of the cannabinoid oil, or terpenes may be included in the composition at up to a quantity of 50% by volume.
-5-Table 1 Desired Potency Cannabinoid Oil 1,3-Propanediol Dilution Ratio High 1 ml 0.5 ml 1:0.5 1 ml 1 ml 1:1 Medium 1 ml 1.25 ml 1:1.25 1 ml 1.5m1 1:1.5 Low 1 ml 1.75m1 1:1.75 1 ml 2m1 1:2 A vaporizable cannabinoid liquid formulation for refillable cartridges or disposable electronic cigarettes or for using directly on atomizers or other controlled temperature vaporizers, including cartomizers or wick systems, that is safer, bio-based, and more effective than currently used products is disclosed herein.
Particularly, the liquid formulation is devoid of polyethylene glycol (PEG) and/or propylene glycol (PG), which are currently widely used for mixing with cannabis oil as a mixing or cutting agent. PEG and PG, in some studies, have demonstrated toxicity as well as skin irritant and carcinogenic effects. The formulation may comprise bio-based 1,3-propanediol for use as an electronic cigarette cannabis liquid, as previously mentioned. This liquid composition for an electronic cigarette may include the use of 1,3-propanediol, as well as one or more combinations of oil or concentrates derived from cannabis including delta-9-tetrahydrocannabinol (THC), Cannabidiol (CBD) and other cannabinoids found in the 483 known compounds occurring in the cannabis plant.
The use of 1,3-propanediol as a mixing or cutting agent in step 30 is instrumental in acting as a carrier, delivering cannabinoid to the user via vaporization and inhalation, allowing it to be absorbed effectively to deliver the required dosage.
Particularly, the liquid formulation is devoid of polyethylene glycol (PEG) and/or propylene glycol (PG), which are currently widely used for mixing with cannabis oil as a mixing or cutting agent. PEG and PG, in some studies, have demonstrated toxicity as well as skin irritant and carcinogenic effects. The formulation may comprise bio-based 1,3-propanediol for use as an electronic cigarette cannabis liquid, as previously mentioned. This liquid composition for an electronic cigarette may include the use of 1,3-propanediol, as well as one or more combinations of oil or concentrates derived from cannabis including delta-9-tetrahydrocannabinol (THC), Cannabidiol (CBD) and other cannabinoids found in the 483 known compounds occurring in the cannabis plant.
The use of 1,3-propanediol as a mixing or cutting agent in step 30 is instrumental in acting as a carrier, delivering cannabinoid to the user via vaporization and inhalation, allowing it to be absorbed effectively to deliver the required dosage.
-6-Performing this task without the harmful carcinogens known to exist in the current (PG) propylene glycol and/or (PEG) polyethylene glycol additives being sold in the marketplace today. 1,3-propanediol delivers a more effective dose of cannabinoid to the patient or user allowing the benefit of providing a much cleaner, safer, non-toxic delivery method being able to treat an array of medical symptoms or conditions without the harmful effects associated with physically smoking marijuana.
A number of tests have been carried out to assure this product is far superior from a safety perspective in comparison to the currently used products. Skin irritation tests show that 1,3-propanediol is not an irritant. Currently used products, such as non-bio-based PG, are known skin irritants. These tests affirm the safety of this product for inhalation via vaping or long-term inhalation exposure of 1,3-propanediol. In 2005, the Journal of Inhalation Toxicity published a research article by: Robert S. Scott, Steven R. Frame, Paul E.
Ross, Scott E. Loveless and Gerald L. Kennedy entitled "Inhalation Toxicity of 1,3-Propanediol in the Rat". 1,3-propanediol was studied to determine the potential effects following repeated inhalation exposures to rats. Rats were exposed 6 hr/day, 5 days/wk for 2 wks (9 exposures) to vapor or vapor/aerosol mixtures of either 0, 41, 650, or 1800 mg 1,3-propanediol/m3. In vivo responses were observed or measured daily. Clinical pathology and tissue pathology analyses were conducted after the 9th exposure and on half of each group following an 18-day recovery (non-exposure) period. All rats showed normal body weights. No unusual external signs of response were seen, and no deaths were encountered. Clinical pathology (blood counts, serum chemical parameters) and tissue pathology (gross pathology, organ weights, and histopathology) examinations in the 1,3-propanediol exposed rats were similar to those in the unexposed controls.
According to the journal, "Inhalation Toxicity of 1,3-Propanediol in the Rat"
as referenced above, the highest concentration tested, 1800 mg/m3, which was the highest concentration that could practically be generated, was the no-observed-effect level (NOEL) for this study. 1,3-propanediol does not appear to
A number of tests have been carried out to assure this product is far superior from a safety perspective in comparison to the currently used products. Skin irritation tests show that 1,3-propanediol is not an irritant. Currently used products, such as non-bio-based PG, are known skin irritants. These tests affirm the safety of this product for inhalation via vaping or long-term inhalation exposure of 1,3-propanediol. In 2005, the Journal of Inhalation Toxicity published a research article by: Robert S. Scott, Steven R. Frame, Paul E.
Ross, Scott E. Loveless and Gerald L. Kennedy entitled "Inhalation Toxicity of 1,3-Propanediol in the Rat". 1,3-propanediol was studied to determine the potential effects following repeated inhalation exposures to rats. Rats were exposed 6 hr/day, 5 days/wk for 2 wks (9 exposures) to vapor or vapor/aerosol mixtures of either 0, 41, 650, or 1800 mg 1,3-propanediol/m3. In vivo responses were observed or measured daily. Clinical pathology and tissue pathology analyses were conducted after the 9th exposure and on half of each group following an 18-day recovery (non-exposure) period. All rats showed normal body weights. No unusual external signs of response were seen, and no deaths were encountered. Clinical pathology (blood counts, serum chemical parameters) and tissue pathology (gross pathology, organ weights, and histopathology) examinations in the 1,3-propanediol exposed rats were similar to those in the unexposed controls.
According to the journal, "Inhalation Toxicity of 1,3-Propanediol in the Rat"
as referenced above, the highest concentration tested, 1800 mg/m3, which was the highest concentration that could practically be generated, was the no-observed-effect level (NOEL) for this study. 1,3-propanediol does not appear to
-7-pose a significant hazard via inhalation of either the vapor or a vapor/aerosol mixture.
The cannabinoid extracts described within may include active ingredients from the marijuana plant extracted using any known extraction method in step 22 of Figure 1: butane, supercritical carbon dioxide (CO2), alcohol or ethanol, distillate, powdered isolates and concentrates.
Butane (BH0) extraction method can be described where the essential oil from the cannabis plant is extracted using Butane as a solvent. It can be extracted from fresh material or from cured material as a concrete or an oleoresin. A
concrete or an oleoresin that has been winterized to remove the waxes, lipids, and fats, is known as an Absolute.
Supercritical CO2 extraction can be described where the essential oil from the cannabis plant is extracted using CO2 as a solvent. This process creates phase changes in carbon dioxide utilizing temperature and pressure. CO2 is known as a "tunable solvent" making it extremely versatile for creating a multitude of end products by controlling temperature and pressure. These phase changes create an environment to drop out differing weights of components in the plant material.
The alcohol or ethanol extraction method can be described where the essential oil from the cannabis plant is extracted by dissolving the plant material in alcohol. Once the material is dissolved the alcohol is boiled off leaving a concentrated cannabinoid oil.
The distillate extraction process of step 24 can be described where the distillation of cannabinoid oil derived from any of the above-mentioned methods requires the oil be heated to a high temperature under a reduced pressure created by a vacuum pump. This causes the THC (delta-9-tetrahydrocannabinol) and related cannabinoid substances to vaporize. The vapors are condensed back into an oil on contact with a cooled surface in step
The cannabinoid extracts described within may include active ingredients from the marijuana plant extracted using any known extraction method in step 22 of Figure 1: butane, supercritical carbon dioxide (CO2), alcohol or ethanol, distillate, powdered isolates and concentrates.
Butane (BH0) extraction method can be described where the essential oil from the cannabis plant is extracted using Butane as a solvent. It can be extracted from fresh material or from cured material as a concrete or an oleoresin. A
concrete or an oleoresin that has been winterized to remove the waxes, lipids, and fats, is known as an Absolute.
Supercritical CO2 extraction can be described where the essential oil from the cannabis plant is extracted using CO2 as a solvent. This process creates phase changes in carbon dioxide utilizing temperature and pressure. CO2 is known as a "tunable solvent" making it extremely versatile for creating a multitude of end products by controlling temperature and pressure. These phase changes create an environment to drop out differing weights of components in the plant material.
The alcohol or ethanol extraction method can be described where the essential oil from the cannabis plant is extracted by dissolving the plant material in alcohol. Once the material is dissolved the alcohol is boiled off leaving a concentrated cannabinoid oil.
The distillate extraction process of step 24 can be described where the distillation of cannabinoid oil derived from any of the above-mentioned methods requires the oil be heated to a high temperature under a reduced pressure created by a vacuum pump. This causes the THC (delta-9-tetrahydrocannabinol) and related cannabinoid substances to vaporize. The vapors are condensed back into an oil on contact with a cooled surface in step
-8-26. Selecting the appropriate temperature and pressure for the distillation collects the desired fraction. Many of the impurities do not vaporize and are left behind in the flask used for heating the oil. The result is cleaner, purer, clearer solvent-free oil.
The cannabinoid extracts may also be prepared as a powdered isolate by contacting a cannabinoid containing plant with supercritical CO2 to produce a crude cannabinoid extract, subjecting the crude cannabinoid extract to thin film evaporation to produce a refined cannabinoid extract. The refined cannabinoid 1 0 extract is then dissolved in a solvent and crystallization induced in the solution to form cannabinoid crystals.
Under the umbrella of cannabinoid concentrates falls any product procured through an extraction process. Solvents, (e.g., butane, CO2, ethanol) strip compounds from the cannabis plant, leaving behind a product with cannabinoids packed in every drop. Some types of extracts test as high as 80%
in THC, while others are rich in non-psychoactive compounds like CBD
(cannabidiol) deliver an altogether "high-less" experience. The exact specifications, materials used, and method of use of the electronic cigarette mixing agent composition system may vary upon manufacturing.
While specific embodiments of the invention have been described and illustrated, such embodiments should be considered illustrative of the invention only and not as limiting the invention as construed in accordance with the accompanying claims.
The cannabinoid extracts may also be prepared as a powdered isolate by contacting a cannabinoid containing plant with supercritical CO2 to produce a crude cannabinoid extract, subjecting the crude cannabinoid extract to thin film evaporation to produce a refined cannabinoid extract. The refined cannabinoid 1 0 extract is then dissolved in a solvent and crystallization induced in the solution to form cannabinoid crystals.
Under the umbrella of cannabinoid concentrates falls any product procured through an extraction process. Solvents, (e.g., butane, CO2, ethanol) strip compounds from the cannabis plant, leaving behind a product with cannabinoids packed in every drop. Some types of extracts test as high as 80%
in THC, while others are rich in non-psychoactive compounds like CBD
(cannabidiol) deliver an altogether "high-less" experience. The exact specifications, materials used, and method of use of the electronic cigarette mixing agent composition system may vary upon manufacturing.
While specific embodiments of the invention have been described and illustrated, such embodiments should be considered illustrative of the invention only and not as limiting the invention as construed in accordance with the accompanying claims.
Claims (15)
1. A method for forming a vaporizing article comprising:
collecting a cannabinoid distillate from a plant product;
introducing a quantity of 1,3 propenediol to said cannabinoid distillate;
and homogenizing said cannabinoid distillate and said propenediol.
collecting a cannabinoid distillate from a plant product;
introducing a quantity of 1,3 propenediol to said cannabinoid distillate;
and homogenizing said cannabinoid distillate and said propenediol.
2. The method of claim 2 wherein said cannabinoid is selected from the group consisting of delta-9-tetrahydrocannabinol (THC) and Cannabidiol (CBD).
3. The method of claim 2 wherein said cannabinoid has a purity of at least 99%.
4. The method of claim 2 wherein said cannabinoid comprises between 0 and 99 percent by volume of said vaporizing article.
5. The method of claim 1 further comprising introducing at least one terpene to said cannabinoid distillate and propenediol.
6. The method of claim 5 wherein said terpene is collected from a distillation process utilized to collect said cannabinoid distillate.
7. The method of claim 5 wherein said at least one terpene comprise between 0 and 50 percent by volume of said vaporizing article.
8. The method of claim 1 further comprising introducing a quantity of an emulsifying agent to said vaporizing article before homogenizing.
9. A vaporizable composition comprising cannabinoid and 1,3 propenediol.
10. The vaporizable composition of claim 9 wherein said cannabinoid is selected from the group consisting of delta-9-tetrahydrocannabinol (THC) and Cannabidiol (CBD).
11. The vaporizable composition of claim 9 wherein said cannabinoid comprises between 0 and 99 percent by volume of said vaporizing article.
12. The vaporizable composition of claim 9 further comprising a quantity of at least one terpene.
13. The vaporizable composition of claim 12 wherein said terpene is collected from a distillation process utilized to collect said cannabinoid distillate.
14. The vaporizable composition of claim 12 wherein said at least one terpene comprise between 0 and 50 percent by volume of said vaporizing article.
15. The vaporizable composition of claim 9 further comprising a quantity of an emulsifying agent.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762462255P | 2017-02-22 | 2017-02-22 | |
| US62/462,255 | 2017-02-22 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA2995970A1 true CA2995970A1 (en) | 2018-08-22 |
Family
ID=63245253
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA2995970A Abandoned CA2995970A1 (en) | 2017-02-22 | 2018-02-22 | Electronic cigarette mixing agent composition systems |
Country Status (2)
| Country | Link |
|---|---|
| CA (1) | CA2995970A1 (en) |
| WO (1) | WO2018152637A1 (en) |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2020093170A1 (en) * | 2018-11-09 | 2020-05-14 | Cronos Group Inc. | Liquid composition for an electronic vapor device |
| WO2022232574A1 (en) * | 2021-04-29 | 2022-11-03 | Tilray, Inc. | Cannabidiol-dominant formulations, methods of manufacturing, and uses thereof |
| US12029720B2 (en) | 2022-04-29 | 2024-07-09 | Tilray Brands, Inc. | Cannabidiol-dominant formulations, methods of manufacturing, and uses thereof |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US10239808B1 (en) | 2016-12-07 | 2019-03-26 | Canopy Holdings, LLC | Cannabis extracts |
| EP3745884A1 (en) | 2018-01-31 | 2020-12-09 | Canopy Holdings, Llc | Hemp powder |
| CA3119729A1 (en) | 2018-10-10 | 2020-04-16 | Treehouse Biotech, Inc. | Synthesis of cannabigerol |
| CA3119204A1 (en) * | 2018-11-13 | 2020-05-22 | Hexo Operations Inc. | Method of manufacturing vape oil including a cannabinoid for use in a vape device |
| US11606980B2 (en) * | 2019-08-23 | 2023-03-21 | Mabee Engineered Solutions, Inc. | Vaporizer apparatus having both a vacuum pump and a heating element, and method of using same |
| US11517044B2 (en) * | 2019-08-23 | 2022-12-06 | Mabee Engineered Solutions Inc. | Vaporizer apparatus |
| FR3119517B1 (en) * | 2021-02-08 | 2024-04-12 | Sebastien Ombe | Vaporizable liquid composition for electronic cigarettes containing at least one diol, as well as nicotine and at least one cannabinoid compound free of delta-9-tetrahydrocannabinol. |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9326967B2 (en) * | 2013-08-22 | 2016-05-03 | Stephen C. Perry | Vaporizable cannabinoid compositions |
| WO2015117243A1 (en) * | 2014-02-07 | 2015-08-13 | Bellerose Samuel | Liquid formulation for e-cigarettes |
| GB2524469A (en) * | 2014-02-14 | 2015-09-30 | Kind Consumer Ltd | A cannabinoid inhaler and composition therefor |
| FR3015186A1 (en) * | 2014-03-11 | 2015-06-26 | Antoine Piccirilli | USE OF A COMPOSITION COMPRISING 1,3-PROPANEDIOL AS E-LIQUID |
| WO2016019353A1 (en) * | 2014-07-31 | 2016-02-04 | MJAR Holdings, LLC | Electronic cigarettes, cartridges, and inhalable formulations of medicinal cannabis compounds, and apparatuses and methods for making and using the same |
| CA3186297A1 (en) * | 2016-09-15 | 2018-03-15 | Markham Biotech Inc. | Cannabinoid formulations for aerosol devices and methods thereof |
| US11660403B2 (en) * | 2016-09-22 | 2023-05-30 | Juul Labs, Inc. | Leak-resistant vaporizer device |
-
2018
- 2018-02-22 WO PCT/CA2018/050205 patent/WO2018152637A1/en active Application Filing
- 2018-02-22 CA CA2995970A patent/CA2995970A1/en not_active Abandoned
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2020093170A1 (en) * | 2018-11-09 | 2020-05-14 | Cronos Group Inc. | Liquid composition for an electronic vapor device |
| WO2022232574A1 (en) * | 2021-04-29 | 2022-11-03 | Tilray, Inc. | Cannabidiol-dominant formulations, methods of manufacturing, and uses thereof |
| US12029720B2 (en) | 2022-04-29 | 2024-07-09 | Tilray Brands, Inc. | Cannabidiol-dominant formulations, methods of manufacturing, and uses thereof |
Also Published As
| Publication number | Publication date |
|---|---|
| WO2018152637A1 (en) | 2018-08-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CA2995970A1 (en) | Electronic cigarette mixing agent composition systems | |
| US9333229B2 (en) | Winterized crude cannabis extracts and methods of preparation and use | |
| US11040295B2 (en) | Method and apparatus for extracting plant oils using ethanol water | |
| Giroud et al. | E-cigarettes: a review of new trends in cannabis use | |
| WO2015042589A1 (en) | Personal vaporizer liquid for emulsifying oil-soluble compounds and resins | |
| US20210267935A1 (en) | Cannabis product | |
| TW201138920A (en) | Methods for extracting and isolating constituents of cellulosic material | |
| US20210392943A1 (en) | Liquid composition for an electronic vapor device | |
| WO2019131579A1 (en) | Tobacco extract, method for producing tobacco extract, and non-combustion flavor inhaler including tobacco extract | |
| FR3062303A1 (en) | VAPORIZABLE LIQUID FORMULATION COMPRISING AT LEAST ONE DIOL AND AT LEAST ONE CANNABINOID COMPOUND | |
| JP2022506064A (en) | Aerosolized formulation | |
| KR101623426B1 (en) | Liquid Composition for Atomizing Device and Method for Producing the Same | |
| JP2022506076A (en) | Aerosolized formulation | |
| EP3644975A1 (en) | A composition comprising a scent for use as a substance dependency rehabilitation composition | |
| Rao et al. | Extraction of essential oil and its applications | |
| KR20030040514A (en) | Eye drops | |
| RU2745353C1 (en) | Flavored vaporable composition | |
| WO2021080535A2 (en) | Memory booster essential oil mixture | |
| RU2093171C1 (en) | Medicinal agent | |
| JP7334104B2 (en) | Dementia improving and/or preventing agent | |
| US20230248051A1 (en) | Flavoring solution | |
| EP3918927A1 (en) | E-liquid for vaping comprising an aerosol-forming agent and a method of producing thereof | |
| Li | Aerosolization and Thermal Degradation Chemistry of Electronic Cigarettes | |
| US20230083927A1 (en) | Electronic vapor liquid composition and method of use | |
| Wigglesworth | Vaping Synthetic Cannabinoids: Degradation Study and Putative Production of Toxic Compounds |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FZDE | Discontinued |
Effective date: 20210831 |
|
| FZDE | Discontinued |
Effective date: 20210831 |